Alexion Pharmaceuticals Inc. (ALXN)
ALXN (NASDAQ:Drugs)
$102.62
+2.59
+2.59%
Today's Range: 100.03 - 102.87 |
ALXN Avg Daily Volume: 1,765,400
| Last Update: 05/21/13 - 3:51 PM EDT |
| Volume: 785,485 |
| YTD Performance: 9.77%
|
| Open: $100.52 |
| Previous Close: $100.03 |
| 52 Week Range: $81.82 -
$119.54 |
| Oustanding Shares: 195,146,634 |
| Market Cap: 20,080,588,639 |
6-Month Chart
TheStreet Ratings Grade for ALXN
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
14 |
14 |
15 |
14 |
| Moderate Buy |
1 |
1 |
1 |
1 |
| Hold |
4 |
4 |
4 |
5 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.45 |
1.45 |
1.42 |
1.52 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
12/31/69 |
| Price Earnings Ratio: |
70.48 |
|
| Price Earnings Comparisons: |
| ALXN |
Sector Avg. |
S&P 500 |
| 70.48 |
71.00 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
19.64%
|
18.59%
|
300.16%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
44.80 |
1.93 |
0.43 |
| Net Income |
0.00 |
0.00 |
0.00 |
| EPS |
40.70 |
-0.23 |
-0.08 |
| Earnings for ALXN: |
| EBITDA |
0.42B |
| Revenue |
1.13B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$0.60 |
$0.70 |
$2.67 |
$3.01 |
| Number of Analysts |
4 |
4 |
4 |
4 |
| High Estimate |
$0.62 |
$0.72 |
$2.71 |
$3.16 |
| Low Estimate |
$0.58 |
$0.67 |
$2.60 |
$2.86 |
| Prior Year |
$0.41 |
$0.53 |
$1.86 |
$2.67 |
| Growth Rate (Year over Year) |
46.34% |
32.55% |
43.41% |
12.65% |
| May 13, 2013 | 6:44 PM EDT
We see a lot of short squeezes as money rotates into laggard groups.
| May 10, 2013 | 12:52 PM EDT
Just a natural change in leadership.
Apr 26, 2013 | 7:18 AM EDT
ALXN estimates were increased to reflect increased confidence in manufacturing now that the source of contamination has been identified...
| Apr 09, 2013 | 5:37 PM EDT
Upward momentum is lagging.
Apr 02, 2013 | 11:58 AM EDT
Apr 01, 2013 | 8:07 AM EDT
Shares of ALXN now seen reaching $120, UBS said. Estimates also lowerd on FDA warning letter and EU updates. Buy rating.
| Mar 11, 2013 | 2:12 PM EDT
Charts of Actavis and Alexion show a combination of positive technical factors.
Feb 20, 2013 | 7:44 AM EST
ALXN was downgraded from Buy to Neutral, Lazard Capital Markets said. $102 price target. Stock appears attractive, following a 30% decl...
Feb 15, 2013 | 8:17 AM EST
Shares of ALXN now seen reaching $88, Jefferies said. Estimates also lowered on delay in Soliris launch. Hold rating.
| Jan 22, 2013 | 10:00 AM EST
Here's another batch of names with impressive free cash flow, a crucial metric.
